Arizona, Southeast US will feel greatest impact from ACA exits

| | Health Exec | Policy & Regulations

The effects of major insurers like UnitedHealth, Humana, and most recently, Aetna, departing from some state health insurance exchanges will depend largely on where consumers live.

Phil Galewitz of Kasier Health News writes customers on Affordable Care Act’s insurance marketplaces in more populated areas across the country will still have multiple insurers offering coverage. For those in Arizona, North and South Carolina, Georgia and parts of Florida, however, their options may be limited to only one or two insurers when open enrollment begins Nov. 15.

“The effect on consumers is going to be mixed around the country,” said Katherine Hempstead, a senior adviser at the nonpartisan Robert Wood Johnson Foundation. “Most of these marketplaces are not dependent on” the large national carriers.

For more on how the exits will disproportionately affect rural counties, click on the link below: 

Obamacare Marketplace Shakeout Rocks Arizona, Southeast

Related Content

Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders
Advancing AI for vascular surgery will require a commitment to data integrity

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.